Moderna Announces Q4 2025 Financial Results

SEC 8-K Filing Notice

Company: Moderna, Inc. (MRNA) Filing Date: 2026-02-13 Accession Number: 0001682852-26-000015

Items Filed

Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Summary

Moderna, Inc. filed an 8-K on February 13, 2026, announcing its financial results for the fourth quarter ended December 31, 2025. The announcement was made via a press release furnished as Exhibit 99.1. This filing provides investors and industry stakeholders with insights into Moderna's recent financial performance. The information is furnished, not filed, meaning it's not subject to certain liabilities under the Securities Exchange Act unless explicitly referenced in another filing.

Key Takeaways

Moderna announced its Q4 2025 financial results via press release.
The filing includes the press release as Exhibit 99.1.
The information is furnished under Item 2.02 and not considered 'filed' for liability purposes.
James M. Mock, Chief Financial Officer, signed the report.

Analysis

This 8-K filing is a routine announcement of quarterly financial results. Investors will scrutinize the press release (Exhibit 99.1) for key performance indicators such as revenue, earnings per share, and future guidance. Competitors will analyze Moderna's performance to benchmark their own results and strategies. The broader pharmaceutical market will be interested in Moderna's commentary on market trends, particularly in mRNA technology and vaccine development. The 'furnished' status of the information provides a degree of legal protection to Moderna, but the market will still react based on the content of the press release.

This post was automatically generated from an SEC 8-K filing.